Novartis has announced its intention to acquire U.S.-based biotech Excellergy for up to $2 billion, focusing on a next-generation allergy treatment that could outperform existing options. This acquisition, which includes the early-stage drug candidate Exl-111, is part of Novartis’ strategy to bolster its portfolio amid impending patent expirations affecting several key drugs. Just a week prior, Novartis revealed another acquisition of Pikavation Therapeutics for up to $3 billion, further emphasizing its commitment to expanding its therapeutic offerings.
This move comes at a critical time for Novartis, as it faces significant revenue losses due to the “patent cliff,” with several of its best-selling drugs set to lose exclusivity by 2026. The company is actively pursuing bolt-on acquisitions to enhance its pipeline and mitigate the impact of generics on its earnings. Despite these strategic maneuvers, Novartis stock remained stable during morning trading in Zurich, reflecting investor caution amid ongoing challenges.
For market professionals, the key takeaway is that Novartis is positioning itself to counteract revenue declines through strategic acquisitions, highlighting the ongoing trend of consolidation in the pharmaceutical sector as companies seek to secure promising drug candidates before facing generic competition.
Source: cnbc.com